Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

Current fair value: .18

One Year Price Target: $2.00

I expect by June 1, 2014 that $AMBS be trading on the NASDAQ and funds will own more than 60% of the outstanding shares. The market cap will be in the $1,000,000,000 range.

You ask how does this happen?

A license agreement with Becton Dickinson for LymPro, a number of grants to develop MANF, and additional "orphan indications" for MANF moves the share price to the $1.00 range by April 1,2014.

The company announces a 1 for 10 reverse split and an uplisting to the NASDAQ. The share price hits $1.50 on the news and the company starts trading on the NASDAQ at $15.00 with approximately 45,000,000 shares outstanding. The funds start buying the stock in anticipation of a "big pharma" partnership to develop Lympro or a possible takeover. The share price moves to $25.00 range.

The company signs a development partnership with a company such as Amgen, Sanofi, or Glaxo.

Eventually the company is bought for $75.00/share or $3,000,000,000. The other possibility is that the company stays on it's own and develops "MANF" to treat numerous diseases and eventually reaches a $100,000,000,000 market cap.

"Patience is a virtue."

Know what you own.